Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Teligent Acquires Alveda Pharmaceuticals | Contract Pharma

What are you searching for?

Sign in
Breaking News

Teligent Acquires Alveda Pharmaceuticals

Extends reach to Canadian market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

New Jersey-based specialty generic pharmaceutical company Teligent Inc., has acquired Alveda Pharmaceuticals Inc. for approximately $35 million. The deal gives Teligent a platform to expand its specialty generic pharmaceutical portfolio of products across Canada.

“We look forward to building on the successful business that the Alveda team has created over the last several years,” said Jason Grenfell-Gardner, president and chief executive officer, Teligent. ”We see great opportunities to integrate our R&D capabilities with the commercial and regulatory strengths of our new colleagues in Canada.”

Mike Bethell has been named general manager, Canada for Teligent. “Mike has been with Alveda from the beginning. He has played a significant role in driving the company’s growth, and we look forward to his leadership and market expertise to further build our business in Canada,” said Mr. Grenfell-Gardner.

Alveda had sales of approximately $12 million in fiscal 2015. Its pipeline includes 8 injectable products, 4 of which are under review by Health Canada. In addition, the business currently sells a portfolio of 17 molecules—36 injectable presentations—in the Canadian market. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics